Nesfatin-1

Nesfatin-1 is an 82-amino-acid peptide derived from the N-terminal region of nucleobindin-2 (NUCB2). It was reported in 2006 by Oh-I and colleagues, who identified it while searching for hypothalamic transcripts regulated by compounds that alter feeding. The name derives from NEFA/nucleobindin-2-encoded satiety- and fat-influencing protein.

In the original rodent studies, nesfatin-1 reduced food intake and body-weight gain, and immunoneutralisation increased feeding, suggesting a physiological role in satiety. The peptide and its precursor are expressed in several hypothalamic and brainstem nuclei involved in energy balance, including the paraventricular, supraoptic and arcuate nuclei and the nucleus of the solitary tract, as well as in peripheral tissues such as gastric endocrine cells, pancreatic islets and adipose tissue. Nesfatin-1 remains a in vitro studies and animal models.">preclinical research peptide. Its evidence base is comparatively limited, its receptor has not been identified, and findings across laboratories have not always been consistent, making it an active area for careful basic research into neuroendocrine peptide biology.

The receptor for nesfatin-1 remains unknown, although pharmacological studies suggest involvement of a G protein-coupled mechanism. In rodent models its anorexigenic effect appears to be independent of leptin signalling but to depend on central melanocortin pathways, as melanocortin 3/4 receptor antagonism blunted the response. Nesfatin-1 also activates oxytocin neurons in the paraventricular nucleus, and oxytocinergic projections to the brainstem have been proposed as a downstream relay. Additional studies report effects on stress-axis activity, gastric motility and glucose-stimulated insulin secretion from islet cells. Because NUCB2 itself is a calcium-binding protein with intracellular functions, distinguishing peptide-specific signalling from precursor biology is an ongoing methodological challenge.